Welcome to our dedicated page for Skye Bioscience SEC filings (Ticker: SKYE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Skye Bioscience, Inc. filings document regulatory disclosures for a clinical-stage biopharmaceutical company developing G-protein-coupled receptor modulators for obesity and metabolic health. Form 8-K reports cover financial results, corporate updates, Reg FD clinical communications for nimacimab and the CBeyond program, and material events tied to executive transitions, equity compensation and Nasdaq listing-compliance matters.
The company's proxy materials address annual meeting voting, director elections, executive compensation, pay-versus-performance tables, equity awards and incentive-plan governance. Compensation-related filings also describe stock-option repricing under Skye equity incentive plans and related common-stock disclosures.
Skye Bioscience reported that Nasdaq has notified the company it no longer meets the Nasdaq Global Market stockholders’ equity requirement. Based on its Form 10-Q for the quarter ended March 31, 2026, stockholders’ equity was $9,011,804, below the $10,000,000 minimum under Listing Rule 5450(b)(1)(A).
The notice does not immediately affect trading, and the stock continues on the Nasdaq Global Market under the symbol SKYE. Skye has 45 days, until June 29, 2026, to submit a plan to regain compliance, with a potential extension of up to 180 days, to November 9, 2026, if Nasdaq accepts its plan. Failure to regain compliance could ultimately lead to delisting after any appeal process.
Skye Bioscience, Inc. filed an initial Form 3 for Chief Financial Officer John P. Sharp. This filing establishes him as a reporting person for the company’s equity securities. The filing shows no reported transactions or holdings in either common stock or derivative securities at this time.
Skye Bioscience is asking stockholders to vote at a fully virtual 2026 annual meeting while outlining clinical and strategic progress for its obesity program. The company highlights proof-of-concept data for nimacimab, a peripheral CB1 antibody, in combination with semaglutide.
In the CBeyond study, the combination arm reached 22.3% mean weight loss at 52 weeks with additional benefits in waist circumference and lean-to-fat mass ratio, and a safety profile described as placebo-like with no observed nimacimab-associated neuropsychiatric signal. Skye is running a higher-dose expansion, advancing subcutaneous delivery options, and preparing a Phase 2b design incorporating FDA feedback.
On governance, stockholders are asked to elect six directors, ratify CBIZ CPAs P.C. as auditor, approve an amendment to increase authorized common shares from 100,000,000 to 300,000,000, and cast an advisory vote on executive compensation. The board describes its committees, independence, anti-hedging and clawback policies, and a director compensation structure built around cash retainers and stock options.
Skye Bioscience filed its 2026 proxy statement and CEO letter summarizing 2025 progress and items for shareholder vote. The letter highlights CBeyond™ proof-of-concept results for nimacimab combined with semaglutide (26-week additional weight loss; 22.3% mean weight loss at 52 weeks in the combination cohort) and an encouraging safety profile through 52 weeks. The company says the 200 mg weekly monotherapy dose likely underexposed peripheral tissues and has initiated a higher-dose expansion to generate safety and PK data and inform a planned Phase 2b, while advancing a high-concentration formulation and evaluating Halozyme’s ENHANZE® technology for higher-exposure subcutaneous delivery.
The proxy solicits votes to elect six directors, ratify CBIZ CPAs P.C. as auditor, approve an amendment to increase authorized common shares from 100,000,000 to 300,000,000, and to hold an advisory say-on-pay vote. The CEO letter also describes early proof-of-concept for an antibody-peptide conjugate program and ongoing capital discipline and execution priorities for 2026.
Skye Bioscience, Inc. is soliciting proxies for its 2026 virtual annual meeting to elect six directors, ratify CBIZ CPAs P.C. as auditor and seek stockholder approval to amend the Articles of Incorporation to increase authorized common shares from 100,000,000 to 300,000,000. The proxy and CEO letter highlight clinical progress for nimacimab including a 22.3% mean weight loss at 52 weeks in a combination cohort and a move to higher-dose expansion to inform Phase 2b design.
The company emphasizes preparing a Phase 2b plan, advancing higher-concentration subcutaneous formulation work with Halozyme ENHANZE® technology, and developing an antibody-peptide conjugate program. The board recommends voting "For" all proposals; record date and meeting logistics are provided in the proxy materials.
Skye Bioscience, Inc. filed an amended current report to correct a clerical error in an earlier disclosure about stock options. The company now states that the total number of shares of common stock underlying all repriced options is 2,458,158 shares. No other aspects of the prior report were changed.
Skye Bioscience, Inc. approved a broad stock option repricing and appointed a new chief financial officer. Effective March 31, 2026, all eligible employee stock options granted before December 31, 2025 under the company’s incentive plans had their exercise prices reset to $0.6150 per share, matching the common stock’s closing price that day. This affects 2,420,978 shares in total, including options for the CEO and COO, and is intended to retain and motivate employees without issuing additional equity or cash compensation.
On the same date, the board named John P. Sharp as Chief Financial Officer and principal financial and accounting officer. His services are provided through a Master Services Agreement with Lohman & Associates, under which the company pays $25,600 per month for up to 64 hours of CFO and related advisory services.
Skye Bioscience director Karen L. Smith received a grant of stock options covering 75,000 shares of Common Stock. The options have an exercise price of $0.615 per share and expire on March 31, 2036. They vest in equal monthly installments over the one-year period beginning March 31, 2026. Following this grant, she holds 75,000 stock options directly.